Vonoprazan Tablets 10Mg – VOPREXIA 10 Tablets

VOPREXIA 10 Tablets
Composition:- Vonoprazan Fumarate 10mg

VOPREXIA 10 Tablets contains Vonoprazan Tablets 10 mg, a next-generation Potassium-Competitive Acid Blocker (P-CAB). Unlike conventional proton pump inhibitors (PPIs), Vonoprazan blocks the gastric H⁺/K⁺-ATPase pump in a potassium-competitive and reversible manner. It does not require acid activation, works rapidly regardless of meal timing, and maintains a more consistent and powerful acid suppression throughout the day.

Marketed by: Wonne International Pvt. Ltd.

Key Points of Vonoprazan Tablets 10Mg – VOPREXIA 10 Tablets

• Next-generation acid suppression — P-CAB mechanism provides stronger, faster, and more consistent acid control compared to conventional PPIs
• No meal-timing restriction — Does not require activation by acid; can be taken at any time, with or without food, improving patient compliance.
• Rapid onset of action: Achieves effective acid suppression within hours of the first dose, unlike PPIs, which may take several days to reach full effect.
• Not affected by CYP2C19 polymorphism — Metabolism is independent of CYP2C19 genotype, ensuring uniform efficacy across all patient populations.
• Broad acid-related indications — Indicated in GERD, erosive oesophagitis, gastric ulcer, duodenal ulcer, and H. pylori eradication

Can be Prescribed by:

• Gastroenterology
• General Practice
• Internal Medicine
• Critical Care

Disclaimer: To be used under medical supervision only and not intended for general public promotion. This content is meant for registered healthcare professionals only.